THOUGHT LEADERSHIP

A look into the critical factors of complex supply channels and the opportunities within these channels to support oncology drug programs.

Webinar Archive: Four essential steps to creating a patient support HUB that meets the unique needs of a manufacturer’s patients and prescribers.

The key to optimizing strategic pharma partnerships to improve quality, manage costs, and enhance patient outcomes.

Risk vs. Reward: Archbow Consulting experts detail four essential contracting best practices for achieving financial savings and long-term protection.

The critical factors at play that manufacturers need to know as they consider pivoting to an Alternative Distribution Model.

The key to successfully selecting and managing the right commercial partners for your product and organizational needs.

Webinar Archive: How to get answers to the eleven key questions that will help guide commercial teams in effectively launching specialty products.

Best practices, lessons learned, and real-world insights gained from assisting multiple manufacturers improve their specialty pharmacy network performance.

The key to successfully building an integrated model for new products is understanding which steps in launch planning are essential and when to take them. 

A recommended checklist for manufacturers as they enlist distributor and 3PL support - and the important questions they should be asking themselves

Practical lists of questions spanning distribution, access, and affordability that Market Access teams can use to begin impacting health inequity today.

Trade and distribution teams are facing more pressure than ever to leverage essential distribution and dispensing partnerships. 

Review common barriers to program success and explore ways to better design patient support programs that actually drive product access.

This whitepaper is a guide for market access teams to perform check-ups on the programs that can most impact product success.

Bringing CGTs to market was never going to be easy, but there’s no reason to repeat these common market access mistakes.

By following the 6 strategies in this whitepaper, pharma companies can improve collaboration and the overall patient journey

Cell and Gene Therapy manufacturers can make changes now, regarless of clinical trial phase, that will better prepare products for commercial success

Actionable insights that create opportunities for greater collaboration between HSSPs, payers, and pharmaceutical manufacturers.

As November 2023 nears, it is essential for all manufacturers to understand the requirements to comply with the Drug Supply Chain Security Act

In today's marketplace, providing patient support services via a HUB is a market access reality for virtually all specialty products.